AstraZeneca Might Pay $340 Million to Avanir
- Share via
AstraZeneca will pay as much as $340 million to Avanir Pharmaceuticals to develop experimental heart-disease treatments.
The companies will work to develop medicines from so-called reverse cholesterol transport enhancing compounds, which may allow the body to reverse damage to blood vessels, AstraZeneca said.
AstraZeneca will pay $10 million now with as much as $330 million linked to the experimental drugs meeting development goals, the companies said. San Diego-based Avanir may get low double-digit royalties from sales of the drugs.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
